Improving Time to Diagnosis In IPF: Is There a Role for Genomics?

e-Learning

This course is available for free as part of the CHEST e-Learning Library.
Access this and other e-learning activities by clicking the button below.

View e-Learning Library

This learning activity highlights the role of genomics in the diagnosis of interstitial lung diseases (ILDs) focusing on idiopathic pulmonary fibrosis (IPF). A prompt and accurate diagnosis of IPF is essential and allows for earlier initiation of antifibrotic therapy to slow down disease progression and improve survival, as well as other important outcomes. Diagnosing IPF is a complex process that is often confounded by other conditions (especially by other ILDs) with similar clinical, radiologic, and pathologic presentations. Delays in diagnosis have been well documented. New technology that utilizes genomic testing may improve clinicians’ ability to distinguish IPF from other ILDs without the need for invasive surgery.

Developed by the American College of Chest Physicians in partnership with Veracyte.

Course Objectives

After completing this online course, you will be able to:

Identify genetic abnormalities associated with ILD and IPF, and determine the commonality of abnormality.
Identify the clinical implications of having a genetic abnormality.
Recognize how a new genomic classifier for UIP detection can assist with differentiating IPF from other ILDs.

Item Number: 7207.60

Faculty

Naftali Kaminski, MD
Boehringer-lngelheim Endowed Professor of Internal Medicine Chief of Pulmonary, Critical Care and Sleep Medicine
Department of Medicine
Yale School of Medicine
New Haven, CT
Disclosure - Consultant: Third Rock, Boehringer Ingelheim Pharmaceuticals Inc., OptiKira, Theravance Biopharma, LifeMax Laboratories, Inc., Three Lakes Partners; Board Member: Pliant; Employee Relationship: Indalo Therapeutics, Inc.

Anoop M. Nambiar, MD, MS, FCCP
Associate Professor of Medicine
Director of Interstitial Lung Disease Program
UT Health San Antonio
South Texas Veterans Health Care System
San Antonio, TX
Disclosure – Research/Grant: Boehringer Ingelheim Pharmaceuticals Inc., Genentech; Speaker Bureau: Boehringer Ingelheim Pharmaceuticals Inc.

Physician Credit

The American College of Chest Physicians is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American College of Chest Physicians designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit

Provider approved by the California Board of Registered Nursing, Provider Number 16433, for 1.0 contact hour.

Nurse Practitioners

The American Academy of Nurse Practitioners Certification Board (AANPCB) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCB for further guidelines.

Physician Assistants

American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.0 Category 1 credits for completing this activity.

Maintenance of Certification Statement

Successful completion of this CME activity enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

Upon successful completion of this course, CHEST will submit your completion data to ABIM via ACCME's Program and Activity Reporting System (PARS) for MOC points. Please allow 3-5 business days after claiming for points to be reflected on your ABIM record.

DISCLAIMER

The American College of Chest Physicians (“CHEST”) and its officers, regents, executive committee members, members, related entities, employees, representatives and other agents (collectively, “CHEST Parties”) are not responsible in any capacity for, do not warrant and expressly disclaim all liability for, any content whatsoever in any CHEST publication or other product (in any medium) and the use or reliance on any such content, all such responsibility being solely that of the authors or the advertisers, as the case may be. By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any CHEST publication or other product. Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of CHEST Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.

American College of Chest Physicians
2595 Patriot Boulevard
Glenview, IL 60026
Telephone: +1 (224)521-9800; Fax: +1 (224)521-9801
chestnet.org